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Abstract 
Key requirements for the validity of a neuropathological study are the inclusion of large numbers of biopsy or 
autopsy cases and proper controls, the rigorous classification of the basic neuropathology and the selection of 
the most suitable technologies for investigation. Whether the studies are performed with the fanciest, new, 
and state of the art technology or with rather conventional methodology is of minor importance. Following 
these criteria, a spectrum of neuropathological studies has been published in 2020, which provides new in-
sights on important questions related to neurological disease. They include the pathological substrate of brain 
disease in COVID-19 infected patients, the nature of the adaptive and innate inflammatory response, or the 
type and mechanisms of tissue injury and repair in multiple sclerosis, and diagnostically relevant or mechanistic 
new insights into antibody-mediated diseases of the central nervous system.  Other studies describe in detail 
the dynamic changes of brain inflammation in patients with trisomy 21 as a disease model for Alzheimer’s dis-
ease, or the presence and consequences of vascular comorbidities in a chronic inflammatory disease, such as 
multiple sclerosis. All these contributions have provided important, highly relevant clues for basic and transla-
tional neuroscience. 
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1) What was the brain pathology in 
patients who died during the course of 
COVID-19? 
The COVID-19 pandemic has been a major 
challenge for society and particularly for health 
care institutions during the last year. Although 
COVID-19 primarily affects the respiratory system 
and the major cause of death is pneumonia with 
respiratory failure, other organs, such as the renal, 
cardiovascular system, or the digestive tract, are 
affected (Paterson et al. 2020). Most relevant for 
neuropathology is that the nervous system, too, 
can be a target, reflected for instance by anosmia 
and ageusia, encephalopathy, focal ischemic stroke, 
encephalitis, meningitis, or polyneuritis (Li et al. 
2020, Paterson et al. 2020, Liu et al. 2020, Hernan-
dez-Fernandez et al. 2020). To what extent these 
neurological deficits are due to direct SARS-Cov2 
infection of the nervous tissue, immune-mediated 
brain damage in the course of a systemic cytokine 
storm, or are secondary complications of respirato-
ry failure, the intensive care setting, or comorbidi-
ties is not clear (Liu et al. 2020). Neuropathology 
plays a critical role in answering these questions.  
Review 
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The first approach to answer these questions 
was to analyze whether molecules, which are in-
volved in cellular virus infection or propagation, are 
expressed within the nervous system. Angiotensin 
concerting enzyme 2 (ACE2) is one of the cellular 
receptors recognized by SARS-Cov2, when docking 
to the cell surface. Thus, the presence of ACE2 on 
brain cells, such as neurons, glia or cerebral endo-
thelial cells suggests that brain infections is possible 
(Kabbani and Olds 2020, Kanwar et al. 2020). An-
other docking molecule for SARS-Cov2 is Neuropilin 
1 (NRP1) and a high expression of this molecule has 
been found in virus infected cells in the nasal cavity 
in COVID-19 patients (Cantuti-Castelvetri et al. 
2020).  
Early neuropathological studies in the COVID-
19 pandemic were restricted to single case reports 
or investigations in very small patient cohorts, and 
they were generally restricted to some basic neu-
ropathological investigations (Kantonen et al. 2020, 
Reichard et al. 2020, Jensen et al. 2020, Younger 
2020, Liu et al. 2020). The results were diverse and 
controversial, mainly providing evidence for brain 
damage that was not directly linked to SARS-Cov2 
infection. The first systematic study on this issue 
appeared on October 2020 in Lancet Neurology 
(Matschke et al. 2020), and this study combined 
classical neuropathology with virology and molecu-
lar studies on gene expression. In a first set of data 
the authors describe that different molecules, in-
volved in virus docking and propagation, show a 
preferential expression in different cells of the cen-
tral nervous system. For example, ACE2 was mainly 
found in oligodendrocytes. The highest expression 
of transmembrane protease serine subtype 2 and 4 
(TMPRSS2 / 4) was seen in neurons, and NRP-1 was 
mainly present in endothelial cells and astrocytes. 
These data suggest different mechanisms of infec-
tion in different brain cells. The neuropathological 
studies documented the presence of focal and dif-
fuse ischemic lesions and diffuse astrogliosis. Mi-
croglia activation with microglia nodules and in-
flammation were mainly seen in the lower brain 
stem. In about half of the patients, virus was found 
either by PCR or immunocytochemistry. However, 
the virus load was very low and by immunohisto-
chemistry only a very small number of virus infect-
ed cells became apparent. This study is the first to 
describe the basic neuropathology seen in COVID-
19 patients and is, thus, very important and 
groundbreaking. However, it also has important 
limitations. It is based on autopsies of 43 patients, 
which is likely not sufficient to cover the entire 
neuropathological spectrum of the disease. Anoth-
er limitation is that it does not contain data regard-
ing the neurological status of the patients. Thus, it 
remains unclear, to what extent patients with spe-
cific neurological disease manifestations have been 
included. The third limitation is that it does not 
include a proper patient control group and, particu-
larly, patients with similarly severe systemic im-
mune activation. This particular question has been 
addressed in another study on COVID-19 neuropa-
thology, which revealed that the degree of inflam-
mation and microglia activation seen in COVID-19 
patients is similar to that of patients who died un-
der septic conditions (Deigendesch et al. 2020), 
thus suggesting that it may at least in part be a 
secondary consequence of systemic immune acti-
vation. Another study, also based on a large sample 
of autopsies, mainly focused on the possible routes 
of CNS infection (Meinhardt et al. 2020). It shows 
high virus load in the olfactory epithelium, includ-
ing the olfactory sensory neurons, and in the olfac-
tory pathways within the CNS, supporting the view 
of a neuronal route of virus entry into the CNS. 
Additionally, however, virus antigen was also pre-
sent in cerebral endothelial cells, associated with 
micro-thrombosis and cerebral microinfarcts.  
In summary, current pathological studies show 
that the central nervous system can be infected 
with SARS-Cov2, that local infection can be associ-
ated with nervous system damage, but the extent 
of infection is low. A large part of the neuropatho-
logical changes seems to be secondary to systemic 
immune activation and cytokine storm, critical-
illness related encephalopathy, or hypoxia and 
comorbidities. 
2) What new insights have emerged 
into phenotype and disease mecha-
nisms of antibody mediated autoim-
mune diseases of the central nervous 
system? 
The discovery that autoantibodies against 
neuronal ion channels or neurotransmitter recep-
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tors are associated with a spectrum of acute and 
chronic neurological diseases, has revolutionized 
neurological disease research (Höftberger and 
Lassmann 2017). It has been shown that these dis-
eases, which had before been regarded as func-
tional diseases, neurodegenerative disorders or 
toxic conditions, are immune-mediated and can be 
successfully treated with immunosuppression. The 
number of diseases falling into this category has 
profoundly increased during the last years (Höft-
berger and Lassmann 2017). One reason, which 
may in part explain the increase in prevalence, is 
the introduction of immunological checkpoint in-
hibitor therapies in oncology. Immunological 
checkpoints are critical steps in T-cell activation, 
which prohibit the development of auto-reactive T-
cells and auto-antibodies. When these checkpoints 
are inhibited, immune reactions against antigens of 
malignant neoplasms can be triggered, but this may 
occur at the expense of autoimmunity, which is 
frequently directed against neuronal antigens 
(Sechi et al. 2020). 
On this basis it is not surprising that auto-
antibody-associated diseases of the central nervous 
system remained in the focus of research interest 
in 2020. The respective studies provided novel in-
sights into the function of NMDA and glycine recep-
tor directed antibodies in relation to the clinical 
disease spectrum (Matute et al. 2020, Carceles-
Cordon et al. 2020, Rauschenberger et al. 2020) or 
how autoantibodies against IgLON 5 may trigger 
intracellular accumulation of tau-tangles (Landa et 
al. 2020).  
Here, I focus on one study, which deals with 
an interesting but also controversial aspect of these 
diseases. Pitsch et al. (2020) identified antibodies 
against the postsynaptic actin binding protein 
drebrin in patients with severe epileptic seizures, 
which were associated with encephalopathy and 
neuropsychiatric symptoms, including depression 
and cognitive impairment. The antibodies, identi-
fied by selective binding to the neuropil and by 
western blot and sequencing, were specific for 
these patients, and the specificity for the target 
antigen was proven by the lack of binding in 
drebrin knock out mice. Drebrin is an intracellular 
antigen, which is not exposed on the extracellular 
surface of neurons or synapses. For this reason, the 
antibodies themselves may not be pathogenic, but 
just represent a diagnostically useful marker for an 
autoimmune attack of cytotoxic T-cells, as it occurs 
in many classical paraneoplastic diseases. The pa-
thology, described in a biopsy of one of the cases, is 
in line with this assumption, showing infiltrating T-
cells in close contact with neurons. However, the 
study further describes neurophysiological experi-
ments, which show that the antibodies induce al-
tered neuronal activity patterns and increased fir-
ing and bursting rates in neuronal networks in 
vitro. These data suggest that auto-antibodies di-
rected against a cytoplasmic protein in synapses 
may reach their specific target and induce func-
tional changes. The authors suggest that extensive 
exocytosis and endocytosis, which takes place in 
active synapses, facilitates the entry of the antibod-
ies into the intracellular compartment, but this 
proposed mechanism does not explain how the 
antibodies leave the endosomal compartment and 
access the cytosol. This important cell biological 
question with important disease relevance has to 
be clarified in future studies. 
3) What is the pathological difference 
between MOG antibody associated 
inflammatory demyelinating disease 
(MOGAD) and multiple sclerosis (MS)? 
Focal plaques of demyelination with axonal 
preservation and reactive gliosis developing in the 
context of a chronic inflammatory reaction in the 
central nervous system has been regarded as the 
specific hallmark of MS pathology. However, a new 
disease entity has recently emerged, which is an 
inflammatory demyelinating disease associated 
with antibodies directed against myelin oligoden-
drocyte glycoprotein (Reindl and Waters 2019). Not 
all anti-MOG antibodies are pathogenic, but only 
those that are directed against a conformational 
epitope, which is accessible on the surface of native 
oligodendrocytes or on MOG-transfected cell lines. 
Using these diagnostic tests, it became clear that 
MOG antibody-associated disease (MOGAD) differs 
from MS by its clinical manifestation and course as 
well as by its response to immunomodulatory 
treatment (Fujihara and Cook 2020). To explain 
these clinical differences, a neuropathological 
comparison of these diseases is mandatory, but 
Free Neuropathology 2:1 (2021) Hans Lassmann 




respective knowledge on MOGAD was restricted to 
few biopsies with very limited tissue samples. This 
changed in 2020, with two studies describing the 
neuropathological changes in large cohorts of 
MOGAD patients (Höftberger et al. 2020, Takai et 
al. 2020). The lesions in MOGAD differ from those 
seen in MS in many aspects, including their topo-
graphical distribution in the CNS, the type of demy-
elination, and the nature of the inflammatory re-
sponse. In MS, new lesions are formed by simulta-
neous demyelination in large, focal areas or by the 
peripheral expansion of pre-existing lesions located 
throughout the brain and spinal cord. In contrast, 
MOGAD demyelination occurs by confluence of 
small perivenous lesions, generally resulting in a 
demyelination pattern similar to that seen in acute 
disseminated encephalomyelitis (Figure 1). Demye-
lination in MOGAD is associated with complement 
deposition at the site of active myelin injury, but 
the degree of complement activation is much less 
compared to that seen in patients with aquaporin 4 
antibody associated neuromyelitis optica (NMO). In 
both conditions, MS as well as MOGAD, the basic 
lesion is characterized by inflammatory demye-
lination, partial axonal preservation and reactive 
astrocytic gliosis. However, the inflammatory reac-
tion is fundamentally different. While in MS the 
dominant inflammatory reaction is seen around the 
larger drainage veins in the periventricular tissue 
and the meninges, in MOGAD the smaller veins and 
venules are mainly affected. Finally, in MOGAD, 
infiltrating lymphocytes are mainly CD4+ T-cells 
with low numbers of CD8+ T-cells and B-cells; the 
dominant lymphocytes in active MS lesions are 
tissue resident CD8+ effector memory T-cells and B-
cells / plasma cells. All these data indicate that 
MOGAD and MS are fundamentally different dis-
eases.  
Interestingly, the pathology of MOGAD closely 
resembles the pathology seen in experimental 
models of autoimmune encephalomyelitis (EAE), 
induced by immunization of rats, guinea pigs, or 
primates with CNS tissue myelin or recombinant 
MOG (Höftberger et al. 2020). Thus, EAE appears to 
be a very suitable model for MOGAD, but much less 
for MS. Support of this view is provided in a recent 
study, on archival material from a patient, who 
died in the 1950s with an acute MS-like inflamma-
tory demyelinating disease after misguided repeat-
ed immunization with brain tissue (Höftberger et al. 
2015). New molecular biology technologies allowed 
resurrection of a pathogenic auto-antibody from 
the archival formaldehyde fixed and paraffin em-
bedded tissue, which was found to be directed 
against a conformational epitope of MOG and in-
duced demyelination after transfer in vivo (Beltran 
et al. 2020). 
4) Is subpial demyelination a unique 
feature of multiple sclerosis patholo-
gy? 
For a long time, MS has been regarded a de-
myelinating disease affecting the white matter. 
However, with the availability of highly sensitive 
immunocytochemical methods, which allow stain-
ing of the very thin myelinated fibers within the 
grey matter (Peterson et al. 2000), it became clear 
that demyelination in the grey matter in the MS 
brain is extensive (Kutzelnigg et al. 2005) and may 
even give rise to cortico-spinal or pure cortical vari-
ants of the disease in a subset of patients (Trapp et 
al. 2018). Three types of cortical lesions have been 
identified: the cortico-subcortical lesions (Type 1), 
the intracortical lesions (Type 2), and the subpial 
lesions (Type 3) (Bo et al. 2003). The third type is 
most abundant in MS and is related to focal in-
flammatory aggregates in the leptomeninges (Mag-
liozzi et al. 2010; Figure 2). Several previous studies 
have indicated that subpial demyelinated lesions in 
the cortex may be specific for MS (Moll et al. 2008, 
Fischer et al. 2013), but this view was based on a 
rather limited sample of neuropathological condi-
tions other than MS. This has now been changed in 
a very comprehensive study by Junker et al. (2020), 
in which nearly every thinkable neuropathological 
condition has been investigated for cortical demye-
lination. Interestingly, subpial demyelination was 
exclusively present in MS and not seen in any of the 
other conditions. The only key diagnosis missed in 
this case series was MOGAD. However, this was 
also specifically addressed in the systematic studies 
of MOGAD pathology outlined above (Höftberger 
et al. 2020, Takai et al. 2020), describing intracorti-
cal and cortico-subcortical lesions but absent sub-
pial cortical lesions. In rare instances, these intra-
cortical lesions can fuse and give rise to large focal 
confluent plaques of demyelination. Thus, so far it
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Figure 1: Key neuropathological features, distinguishing multiple sclerosis (MS) from the inflammatory demyelinating disease, which is 
associated with auto-antibodies against Myelin Oligodendrocyte Glycoprotein (MOGAD) in the forebrain. 
A) In MS, the lesions (blue areas) are located around large cerebral veins with a predilection site around the ventricle and the subcorti-
cal white matter. They are sharply demarcated from the surrounding peri-plaque white matter and frequently display finger like 
perivenous extensions into the deep white matter. In the cortex, band like subpial lesions (red areas) dominate, mainly located in the 
deep sulci of the cortical ribbon.  
B) In MOGAD, lesions are mainly located in the optic nerves and spinal cord, but their structural details have so far not been clearly 
outlined. When lesions are present in the hemispheres of the forebrain, a type of tissue injury is seen, which resembles acute dissemi-
nated encephalomyelitis. It consists of perivenous sleeves of demyelination around small veins and venules (blue dotted areas), which 
show confluence in the lesion center (dark blue area). When the cortex is affected small perivenous intra-cortical demyelination is seen 
most frequently (red dotted areas). 
C) In MS, the lesions form around larger veins with prominent perivascular spaces. The perivascular spaces contain mainly B-cells (red 
dots) and CD8+ T-lymphocytes (blue dots), the latter also disperse into the plaque parenchyma. CD4+ T-cells (green dots) are very sparse. 
A characteristic feature of active MS lesions is the radial expansion, reflected by a rim of activated macrophages at the lesion edge (blue 
dotted area). 
D) In contrast, in MOGAD, numerous small perivenous sheaths of demyelination are present, which arise around small veins and venules 
(blue dotted areas). In the inflammatory infiltrates the CD4+ T-cells dominate, while there is a much lower contribution of CD8+ T-cells 
(blue dots) or B-cells and plasma cells (red dots). Confluence of the perivenous lesions results in larger demyelinated plaques.       
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seems that subpial cortical demyelination is a 
unique feature of MS pathology, but the evidence 
for its absence in MOGAD is thus far based on a 
rather small sample of cases. Nevertheless, the 
presence of a subpial cortical lesion strongly sup-
ports a neuropathological diagnosis of MS.  
5) What immune cells drive inflamma-
tion in multiple sclerosis? 
Our understanding of the immune mecha-
nisms driving inflammation in MS is largely biased 
by immunological studies of experimental autoim-
mune encephalomyelitis, which now turns out to 
have more relevance for MOGAD than for MS. Key 
mechanisms of inflammation, defined from such 
EAE studies, such as the key role of MHC Class II 
restricted T-cells responses, the involvement of 
CD4+ Th17 cells, or the central role of GM-CSF driv-
en myeloid cell activation (Schreiner and Becher 
2015) are not convincingly supported by recent 
therapeutic trials targeting the respective immuno-
logical pathways (Baker et al. 2017). In contrast, 
most effective therapeutic success is seen with 
drugs that target T-cells and B-cells together or 
even B-cells alone. Thus, it is still an unresolved 
question, as to what cells and immune mechanisms 
trigger or drive inflammation in MS. 
Pathology can help clarify this issue by provid-
ing a concise account of the types of inflammatory 
cells seen in different stages in the evolution of MS 
lesions. Until a few years ago, information about 
the composition of inflammatory infiltrates in MS 
was restricted to small studies performed on a lim-
ited number of patients and lesions. Since 2017, 
however, there are now three large studies availa-
ble, which performed a phenotyping of inflamma-
tory cells in an overall sample of more than 200 MS 
patients and which included all stages of the dis-
ease (Van Nierop et al. 2017, Machado Santos et al. 
2018, Fransen et al. 2020). All studies reached a 
similar conclusion that the dominant lymphocytes 
in the MS lesions are tissue resident CD8+ effector 
memory T-cells (TTRM), while infiltration with CD4+ 
T-cells is sparse. This is the case in all types of MS, 




Figure 2: Patterns of cortical demyelination in MS and MOGAD: 
A) In MS, the dominant and most specific type of cortical demyelination is the subpial lesion. It is characterized by a band of demye-
lination spanning over several gyri and sulci (red lesions). The lesions are more extensive in the invaginations of the cortex. Active corti-
cal demyelination is associated with meningeal inflammation by T-cells (blue dots) and B-cells (red dots) and is characterized by a band 
of activated macrophages / microglia at the border between the cortical lesion and the surrounding normal appearing cortex (purple 
bands). 
B) In MOGAD, the dominant cortical pathology is the presence of small perivenous intracortical demyelinated lesions (red circles). They 
arise around small cortical veins and venules with inflammatory infiltrates. On rare occasions, such intracortical perivenous lesions may 
give rise to a focal confluent cortical lesion, which frequently also expands into the adjacent subcortical white matter. 
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MS as well as primary or secondary progressive MS 
and is the same in all activity stages of the lesions. 
In active lesions, a subset of CD8+ cells show focally 
and temporally restricted activation, and B-cells are 
much more numerous in early stages of the disease 
and in active lesions than in inactive lesions at late 
stages (Machado Santos et al. 2018). In a recent 
study, imaging mass cytometry was applied to the 
biopsy tissue of a single MS patient who suffered 
from a rebound exacerbation after cessation of 
natalizumab treatment (Ramaglia et al. 2019). Also, 
in this study, the infiltrates contained T-cells and B-
cells, but the relative proportion of CD4+ T-cells was 
higher compared to that seen in the previous stud-
ies. However, activation of T-cells, visualized by the 
expression of the transcription factor NFAT or pro-
liferation markers, was seen only in CD8+ T-cells. 
Besides their absolute numbers, the activation 
state of leukocytes is relevant for driving the in-
flammatory reaction. Similarly as before (Machado 
Santos et al. 2018), the most frequent B-cell pheno-
types were IgG+ CD38+ plasmablasts. Thus, overall, 
the pathological data are in line with the observed 
effects of anti-inflammatory treatments in MS pa-
tients. 
6) What do the inflammatory cells in 
MS lesions recognize? 
An important open question is what antigen is 
recognized by the CD8+ tissue resident memory T-
cells. Since such T-cells acquire their phenotype 
and persist after effective clearance of their cog-
nate antigen and become reactivated when the 
antigen re-appears, it is unlikely that these cells 
recognize a classical auto-antigen, which is present 
in the CNS in excess all the time. In line with this 
view, no reactivity of CD8+ T-cells from MS brain 
lesions has been seen against the commonly tested 
myelin antigens (van Nierop et al. 2017). 
Several potential candidate antigens have re-
cently been identified. Since accumulating epide-
miological evidence associates Epstein Barr Virus 
infection with MS (Bar-Or et al. 2020, Levin et al. 
2010), one hypothesis is that B-cells with latent EBV 
infection are present within the CNS of MS patients 
(Serafini et al. 2007, Veroni et al. 2018) together 
with EBV-reactive CD8+ tissue resident effector 
memory T-cells (Serafini et al. 2020). Here, the hy-
pothesis is that inflammatory activity is triggered 
and propagated when the virus is activated in la-
tently infected cells and recognized by the specific 
T-cells (Serafini et al. 2020). As a note of caution, 
several other groups have tried to confirm the spe-
cific presence of EBV infected B-cells in the MS 
brain and lesions and have failed (Lassmann et al. 
2010, van Nierop et al. 2017). The reason for these 
discrepancies is still unresolved.    
In a similar approach, an interaction between 
brain resident CD8+ cells and B-cells has been de-
scribed, where the B-cells did not express EBV (van 
Nierop et al. 2017). This suggests that the cells rec-
ognize a B-cell autoantigen. A possible mechanism 
for how such autoimmunity against B-cells may be 
induced is provided by Jelcic et al. (2018). MS B-
cells, possibly in relation to their EBV infection sta-
tus, expand by auto-proliferation and present a B-
cell specific auto-antigen to CD4+ T-cells, which also 
expand and infiltrate the brain and spinal cord. 
Within the CNS, these T-cells are activated by anti-
gen recognition on infiltrating B-cells. In addition, 
the respective auto-antigen (RASGRP2) is also ex-
pressed in neurons, which may further propagate 
inflammation and tissue injury. Whether this 
mechanism also accounts for activation of CD8+ T-
cells, the dominant inflammatory cells in MS le-
sions, is unknown.   
A different approach has been followed by 
Konjevic Sabolek et al. (2019). In this study, the 
interaction of CD8+ T-cells with local target cells 
was identified by the polarized location of cytotoxic 
granules at the site of contact. When this was seen, 
the target cell was isolated and its nature was de-
termined in gene expression studies and by im-
munohistochemistry. In this study, the only cells 
which interacted with cytotoxic CD8+ T-cells in MS 
lesions were myeloid cells, expressing markers of 
macrophages and microglia, suggesting these may 
harbor the target antigen(s). Finally, other studies 
suggest that the target antigen recognized by T-
cells in MS lesions may be the stress protein alpha 
B crystallin, which is in MS lesions most prominent-
ly expressed in active lesions (van Noort et al. 
2010).   
In summary, the new data from systematic 
phenotypical and functional studies on the inflam-
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matory response within MS lesions provide 
groundbreaking new insights into the pathophysi-
ology of the disease and question the concept of 
MS being an autoimmune disease against myelin. 
However, the results are in part very divergent and, 
to some extent, contradicting. Whether this indi-
cates heterogeneous disease mechanisms between 
individual patients or patient subgroups will be 
seen in the future. 
7) Which microglia or macrophage 
phenotypes are associated with tissue 
damage in the brain? 
Microglia and recruited macrophages play a 
major role in the induction of tissue injury, not only 
in inflammatory brain lesions but also in neuro-
degenerative diseases. For a long time, it was diffi-
cult to distinguish between activated microglia and 
recruited macrophages within brain lesions. This 
has changed with the introduction of markers, 
which are selectively expressed on microglia, such 
as the membrane protein TMEM 119 and the 
marker for homeostatic microglia P2RY12. These 
markers have been used in a number of studies on 
various different inflammatory and neurodegenera-
tive conditions and revealed a surprisingly uniform 
reaction pattern of myeloid cells in human diseases 
(Zrzavy et al. 2017, 2018, Hayashida et al. 2020, 
Jäckle et al. 2020). In essence, at sites of initial tis-
sue injury, resident microglia become activated in a 
pro-inflammatory pattern. This initial step is fol-
lowed by recruitment of myeloid cells from the 
circulation, and the recruited cells also show pro-
inflammatory activation or, at later stages of lesion 
maturation, an intermediate phenotype. The dis-
tinction of pro- versus anti-inflammatory pheno-
types is now seen in a much more critical way, 
since some pro-inflammatory actions, such as the 
interaction of macrophages with target cells may 
contribute to tissue damage but may also be essen-
tial for neuroprotection and regeneration through 
the clearance of debris (Cignarella et al. 2020). An 
important pro-inflammatory type of activation, 
which seems to play a major role in the induction 
of tissue injury, is the expression of proteins in-
volved in oxidative stress, such as the expression of 
the NOX2 complex (NADPH oxidase complex 2), a 
prominent marker of microglia expressed in active 
lesions in different inflammatory conditions as well 
as vascular or neurodegenerative diseases in hu-
mans (Zrzavy et al. 2017, Fischer et al. 2013). To 
define the patterns of microglia activation in such 
diseases may finally result in more selective and 
efficient neuroprotective treatments.  
This is now possible with new technologies, 
such as single-cell RNA sequencing or immunocyto-
chemical methods, which allow the simultaneous 
detection of multiple protein antigens within the 
same section, such as imaging mass cytometry. In 
some studies of models of autoimmune encepha-
lomyelitis and MS, these techniques have been 
used and confirmed in an elegant way the patterns 
of microglia activation and macrophage recruit-
ment, which have been described before with more 
conventional techniques as summarized above 
(Masuda et al. 2019, Ramaglia et al. 2020). Howev-
er, they additionally showed that microglia and 
macrophages with different phenotypes are pre-
sent side-by-side in the same lesion. This may indi-
cate selective activation signals in specific subpopu-
lations of cells. Not surprisingly, the data showed 
that different MS lesions, which were in the same 
activity stage but still displayed some distinct mor-
phological features, were infiltrated by different 
subsets of myeloid cells (Masuda et al. 2019). How-
ever, these studies did not reveal the high expres-
sion of molecules involved in oxidative injury, 
which had been prominent in earlier more conven-
tional neuropathological studies.  
A possible explanation for these discrepancies 
is provided by an elegant study, which specifically 
focused on microglia activation and oxidative injury 
in autoimmune encephalomyelitis (Mendiola et al. 
2020). The authors first defined the molecular phe-
notype of microglia specifically selected from areas 
of oxidative injury. Incorporating this profile in the 
analysis of single-cell RNA sequencing data and 
immunocytochemistry, they identified specific mi-
croglia and macrophage subpopulations, which 
trigger oxidative stress, and showed that these are 
selective subtypes of cells within the population of 
activated myeloid cells. These particular cell types 
also express molecules that are important in the 
coagulation cascade and in glutathione metabo-
lism. In addition, they produce molecules, which 
counteract oxidative stress. One of these molecules 
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Acivivin, a glutathione regulating compound, sup-
presses the inflammatory tissue damage in a model 
of autoimmune encephalomyelitis. It will be in-
strumental in the future to validate directly the 
relevance of these findings in MS lesions and also in 
vascular or neurodegenerative diseases of the cen-
tral nervous system. The presence of a subtype of 
myeloid cells triggering and resolving oxidative 
stress could reconcile the above discrepancies and 
provide a mechanism for the excessive oxidative 
injury in the lesions and the associations of markers 
for oxidative injury with markers for disturbed 
blood coagulation in the lesions. In the long run, 
these data may lead to tools for the therapeutic 
blockade of one of the most detrimental aspects of 
microglia activation in human brain disease. 
8) How do vascular comorbidities in-
fluence multiple sclerosis patients? 
Clinical epidemiology of MS has shown that 
patients with vascular risk factors, such as diabetes, 
hypercholesterolaemia, hypertension, or heart 
disease have a more aggressive disability progres-
sion in comparison to patients lacking these co-
morbidities (Marrie et al. 2010). This is also reflect-
ed by lower brain volumes (Pichler et al. 2019). 
Furthermore, persistence of inflammatory demye-
linating lesions and higher lesion volumes are pre-
sent in brain areas with a blood perfusion that is 
lower than in other brain areas (Haider et al. 2016). 
Such a synergism in neurodegeneration may in part 
be explained by shared effector mechanisms of 
tissue injury between vascular and inflammatory 
diseases, including microglia activation, oxidative 
injury, and mitochondrial damage (Zrzavy et al. 
2017, 2018, Mahad et al. 2015). A strategically im-
portant piece in the puzzle of vascular comorbidi-
ties and MS, which was missing so far, was the lack 
of a comprehensive neuropathological description 
of systemic and intracranial vascular pathology in 
patients versus controls.  
This information has now been provided by a 
study, which is based on a unique archival collec-
tion of MS and control autopsy cases, where de-
tailed information regarding systemic vascular dis-
eases was recorded, and which was collected prior 
to the availability of disease modifying treatments 
(Geraldes et al. 2020). The study shows, as ex-
pected, that systemic and intracranial vascular ab-
normalities increase with age in both the MS and 
the control group. Young MS patients appear to 
have a moderate reduction of systemic vascular co-
morbidities compared to controls, but this differ-
ence disappears with aging. Within the central 
nervous system, MS patients showed a profound 
increase in small arteries with increased perivascu-
lar space, perivascular hemosiderin depositions and 
periarteriolar accumulation of inflammatory cells, a 
type of pathology which correlated in its extent 
with the degree of MS-related pathology. These 
results underline the presence of age-related vas-
cular co-morbidities in the brain of MS patients, 
which may be an amplification factor for neuro-
degeneration and disease progression in aging pa-
tients. Additionally, they indicate that, in contrast 
to the current view, vascular pathology is not re-
stricted to veins but also affects small arteries, and 
this arterial pathology develops at least in part 
independently from systemic vascular risk factors. 
In particular, the mechanisms how inflammatory 
infiltrates accumulate around arteries in the MS 
brain requires further attention. 
9) What is wrong with remyelination 
in multiple sclerosis? 
Primary demyelination with preservation of 
axons is the pathological hallmark of inflammatory 
demyelinating diseases, such as MS. Myelin allows 
saltatory conduction in axons and also protects the 
axons from neurodegeneration. Thus, major efforts 
in MS research have been devoted to develop 
treatments which prevent demyelination or stimu-
late myelin repair (Lubetzki et al. 2020). These re-
pair strategies, mainly designed to provide oli-
godendrocyte progenitor cells in the lesions and to 
stimulate their differentiation into myelinating 
oligodendrocytes, have been developed and tested 
in experimental models of demyelinating disease 
and found to be quite effective. However, none of 
the strategies have yet resulted in clinically mean-
ingful myelin repair in controlled clinical trials in MS 
patients. In experimental models of demyelinating 
disease, profound spontaneous remyelination is 
the rule, and remyelination stimulating therapies in 
essence accelerate myelin repair. Although sponta-
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neous remyelination may also occur in MS patients, 
in particular in fresh lesions at early disease stages, 
remyelination is, in general, sparse or absent. Sev-
eral different mechanisms have been suggested to 
be responsible for this remyelination failure in MS 
lesions. It may be due to a genuine defect in oli-
godendrocyte (progenitor) biology. In an elegant 
study, Starost et al. (2020) approached this ques-
tion by studying oligodendrocytes, induced from 
pluripotent stem cells from MS patients and con-
trols. They show that there is no difference in the 
proliferation, differentiation and myelin production 
between such cells derived from MS patients and 
from controls, thus strongly suggesting that there is 
no genuine defect of oligodendrocytes in MS pa-
tients, though with the caveat that this was only 
performed in cells induced to form oligodendro-
cytes with expression of transcriptional factors 
from three MS patients and three controls. In a 
parallel neuropathological approach, the same 
group analyzed the patterns or remyelination in 
different disease stages of MS and in different 
stages of lesion formation (Heß et al. 2020). They 
found that remyelination is highly efficient in a 
subset of active lesions in the early stage of the 
disease, and their data suggest that the remyelinat-
ing cells may be derived from mature oligodendro-
cytes that had survived active myelin destruction. 
This has also been suggested in recent studies, 
using radiocarbon methods to determine the time 
of birth of new oligodendrocytes in MS lesions 
(Yeung et al. 2019). In contrast, in chronic active 
lesions at later stages of MS, very little remye-
lination was seen and the lack of remyelination was 
associated with pro-inflammatory activity of the 
local microglia population (Heß et al. 2020). These 
data suggest that products of activated inflamma-
tory cells in chronic MS lesions may not only lead to 
their slow expansion but also inhibit the repair of 
myelin. This finding is also supported by the other 
study (Starost et al. 2020), which provides convinc-
ing evidence that pro-inflammatory mediators, in 
particular gamma-interferon, blocks the differenti-
ation of inducible pluripotent stem cells into mye-
linating oligodendrocytes.   
The key importance of these studies is that 
they document that the process of remyelination 
failure in MS is complex and not fully reflected in 
the current experimental models of inflammatory 
demyelinating disease. Thus, for test screening of 
remyelination-promoting therapies different sys-
tems have to be used, which reproduce the in-
flammation-associated remyelination failure. 
10) What can we learn from Down 
Syndrome about inflammation and 
neurodegeneration in Alzheimer’s 
disease? 
A large spectrum of data coming from experi-
mental studies as well as from neuropathological 
and genetic investigations suggest an important 
role of innate immune mechanisms in the patho-
genesis of Alzheimer’s disease (Akiyama et al. 
2000). In particular, microglia phenotype and func-
tion are associated with progression of cognitive 
decline. However, information regarding the time 
course and type of microglia pathology especially in 
the pre-symptomatic phases of the disease is lim-
ited. Analyzing Down syndrome brain pathology of 
patients may provide some answers to these ques-
tions, since a gene dosage effect on amyloid pre-
cursor protein production predictably results in 
early onset Alzheimer’s disease (Wisniewski et al. 
1985, Ballard et al. 2016). 
This approach was followed in a recent study, 
in which the patterns of microglia activation and 
the expression of pro- and anti-inflammatory cyto-
kines was analyzed in a large sample of brain tissue 
of patients with trisomy 21 who had died at differ-
ent ages (Flores Aguilar et al. 2020). Already, in 
juvenile patients, a long time before the first accu-
mulation of soluble Aß or the first deposition of Aß-
plaques, microglia activation and the production of 
proinflammatory cytokines was elevated in com-
parison to age matched controls. In contrast, in 
older patients, when initial Alzheimer’s disease 
pathology became apparent, microglia activation 
decreased and was replaced by senescent microglia 
phenotypes as well as a reduction of the produc-
tion of pro-inflammatory cytokines. These results 
further support the view that anti-inflammatory 
treatment strategies in Alzheimer’s disease may be 
most beneficial when applied in very early (pre-
symptomatic) stages of disease evolution. The data 
further suggest that the inclusion of patients with 
trisomy 21 in future clinical trials could provide a 
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valuable contribution to improve treatment options 
in patients with Alzheimer’s disease. 
Conclusions 
Neuroimmunology is a highly dynamic field 
providing fascinating new insights into the patho-
genesis of brain inflammation and neurodegenera-
tion. The bulk of data, however, describe experi-
mental models and, thus, an additional step is nec-
essary, which defines the relevance of the data for 
human disease. For this, neuropathological studies 
are essential, but they have to be based on system-
atic analysis of a broad spectrum of cases and con-
trols and have to be performed with the most suit-
able molecular or immunological technology. In this 
short review the prime focus was laid on such stud-
ies of human disease, which were sufficiently pow-
ered to provide definite answers to burning ques-
tions of neuroinflammation and inflammatory brain 
diseases. 
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